Please login to the form below

Not currently logged in
Email:
Password:

J&J Risperdal recall

Johnson and Johnson's Ortho-McNeil-Janssen subsidiary has voluntarily recalled one unit each of schizophrenia drugs Risperdal and risperidone 2mg tablets following consumer reports of an 'uncharacteristic odour'

Johnson and Johnson's (J&J) Ortho-McNeil-Janssen subsidiary has voluntarily recalled one unit each of schizophrenia drugs Risperdal and risperidone 2mg tablets in the US following consumer reports of an 'uncharacteristic odour'.

The Risperdal lot includes 16,000 bottles, while the risperidone lot includes around 24,000 bottles.

The incident is the latest in a line of similar recalls from Ortho-McNeil stretching back to early 2010.

J&J said the odour is thought to be caused by trace amounts of TBA (2,4,6 tribromoanisole), a by-product of a chemical preservative sometimes applied to wood often used in the construction of pallets on which materials are transported.

No serious adverse events have been reported following the use of Risperdal and risperidone in relation to TBA, although some patients have reported temporary gastrointestinal symptoms when taking other products with this odour.

J&J recommends patients to not stop taking their medication, and for anyone experiencing an uncharacteristic odour associated with either drug to return the tablets to their pharmacist, and contact their healthcare professional if they have questions. 

The recall comes a week after a safety announcement from the US Food and Drug Administration (FDA) alerting the public to medication error reports in which patients were given Risperdal instead of ropinirole (Requip: GlaxoSmithKline) and vice versa.

20th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics